Thr164Ile polymorphism of the human β2-adrenoceptor exhibits blunted desensitization of cardiac functional responses in vivo

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 285, Issue 5 54-5, 2003, Pages

  Bruck, Heike ^a,b   Leineweber, Kirsten ^a,b   Ulrich, Anke ^b   Radke, Joachim ^b   Heusch, Gerd ^a   Philipp, Thomas ^a   Brodde, Otto Erich ^a,b  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Contractility; Genetic polymorphism; Heart rate

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ISOLEUCINE; TERBUTALINE; THREONINE;

ADULT; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; EXCITATION CONTRACTION COUPLING; FEMALE; GENETIC POLYMORPHISM; HEART BEAT; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART RATE; HETEROZYGOSITY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SYSTOLE;

EID: 0142232036     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00324.2003     Document Type: Article

References (18)

1. Barbato E, Penicka M, Delrue L, Vanderheyden M, Wijns W, Heyndrickx G, Goethals M, De Bruyne B, and Bartunek J. Genetic modulation of human cardiac performance by Ile-164 polymorphism of beta-2 adrenergic receptors (Abstract). Circulation 106: II-327-II-328, 2002.
2. Belz GG. Systolic time intervals: a method to assess cardiovascular drug effects in humans. Eur J Clin Invest 25, Suppl 1: 35-41, 1995.
3. 2-adrenoceptors. Accelerated restoration of β-adrenoceptor responsiveness by prednisone and ketotifen. J Clin Invest 76: 1096-1101, 1985.
4. 2-adrenoceptors. Circulation 103: 1048-1050, 2001.
5. 2-adrenoceptor in vivo function in humans: attenuation by ketotifen. J Cardiovasc Pharmacol 20: 434-439, 1992..
6. 2-adrenoceptor down-regulation. Clin Pharmacol Ther. In press.
7. 2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivo. Pharmacogenetics 13: 59-66, 2003.
8. De Mey C, Belz GG, Nixdorf U, Butzer R, Schroeter V, Meyer J, and Erbel R. Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers. Clin Pharmacol Ther 52: 609-619, 1992.
9. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, Arnold K, Ruano G, and Ligget SB. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 97: 10483-10488, 2000.
10. Green SA, Cole G, Jacinto M, Innis M, and Liggett SB. A polymorphism of the human β2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268: 23116-23121, 1993.
11. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33: 9414-9419, 1994.
12. 2 adrenoceptor gene Thr164Ile polymorphism on human adipose tissue lipolytic function. Br J Pharmacol 133: 708-712, 2001.
13. 2-Adrenergic receptor pharmacogenetics. Am J Respir Crit Care Med 161: S197-S201, 2000.
14. Maisel AS, Fowler P, Rearden A, Motulsky HJ, and Michel MC. A new method for isolation of human lymphocyte subsets reveals differential regulation of beta-adrenergic receptors by terbutaline treatment. Clin Pharmacol Ther 46: 429-439, 1989.
15. Maisel AS, Knowlton KU, Fowler P, Rearden A, Ziegler MG, Motulsky HJ, Insel PA, and Michel MC. Adrenergic control of circulating lymphocyte subpopulations. Effects of congestive heart failure, dynamic exercise, and terbutaline treatment. J Clin Invest 85: 462-467, 1990.
16. 2-adrenoceptor-mediated positive inotropic effects: attenuation by ketotifen. Cardiovasc Res 40: 211-222, 1998.
17. 1-adrenoceptor antagonist treatment. J Am Coll Cardiol 23: 1224-1233, 1994.
18. 2-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 86:834-840, 2000.